Medellín, November 5, 2021
WorldLeish7 organizing committee invites you to the next Pre – WorldLeish 7 Webinar on Monday, December the 6th, at 8:00 a.m. Bogotá – Montréal, 2:00 p.m. Madrid and 4:30 p.m. Tehran.
This time, we will host the conference “Leishmania Extracellular Vesicles» presented by Professors Sima Rafati and Martin Olivier.
Sima Rafati is a full Professor and the head of the Department of Immunotherapy and Leishmania Vaccine Research at Pasteur Institute of Iran. The areas of her expertise are development of new therapies and vaccines to combat leishmaniases. Her sustained efforts on vaccine development and international collaborations have led to innovations based on live non-pathogenic recombinant Leishmania tarentolae, as live vaccine strategies that are being evaluated in relevant disease models. More recently, she has been focusing on host-pathogen interactions and their impacts on the immune responses at the transcriptomic level, in order to define biomarkers of leishmaniases at different levels of the infection in humans. In her presentation, she will speak about her recent contributions on extracellular vesicles of the non-pathogenic L. tarentolae and its differences with the pathogenic L. major.
She will expose us the Leishmania Extracellular vesicles: From transmission to vaccine development.
About her presentation:
Despite worldwide efforts, no vaccine is still available against any form of leishmaniases for human use. In contrast with the pathogenic Leishmania species, the non-pathogenic L. tarentolae is absolutely safe for mammals. Recently, various studies have shown that using L. tarentolae is a promising approach for development of vaccines as a live vector against cutaneous and visceral leishmaniasis in animals, such as mice, hamsters and dogs. Furthermore, L. tarentolae has been shown to act as an efficient delivery system due to its user-friendly manipulability for expressing different molecules in various forms, such as secreted or intracellular components. Many different cell types have been proven to use extracellular vesicles (EV) as vehicles for delivery of modulatory proteins, lipids and nucleic acids to their neighboring cells. So far, all these studies have been focused on and proven, using pathogenic species of Leishmania and there is no evidence about L. tarentolae’s EV and their effects on human macrophages. In this presentation, she will speak about the direct effects of L. tarentolae’s EV on human macrophages and how these bioactive nanovesicles are able to control the parasite propagation, compared to L. major’s EV. Discovering L. tarentolae EV is considered a significant advancement which will pave the way for novel therapeutic applications of L. tarentolae toward vaccine development as well as deliveries of drugs and therapeutic protei
Martin Olivier (B.Sc.,M.Sc.,Ph.D.) is Professor of Medicine, Microbiology and Immunology. He is the chair of the infection and immunity section of the MUHC FOCIS Centre of Excellence in Translational Immunology. His work uses cell biology, immunology and “omic” methods to study pathogenesis of malaria, leishmaniasis and viruses. His research is funded by CIHR and NSERC. He published over 170 original papers and the impact of his research has been celebrated by the reception of awards from the Burroughs Wellcome Fund, The Canadian Society for Immunology and the CSZ Wardle Medal for his exceptional work in the field of immunology and parasitology.
He will expose us to the Leishmania Extracelllular Vesicles: Impact on disease progression.
About his presentation:
Extracellular vesicles (EVs) are small, membrane-bound “delivery trucks” that are present in the extracellular environment, including biological fluids. EVs are capable of inducing changes in the physiological status of neighboring cells through the transfer of key macromolecules, and are thought to play a role in a number of pathological processes. Leishmaniasis, caused by the protozoan parasite Leishmania, is an important example. The biology of Leishmania EVs has been studied in detail, and findings point to their role in exacerbation of disease and potential involvement in the perpetuation of drug resistance. Furthermore, the use of EVs for development of vaccines start to be explored, including their potential use in a number of fields as biomarkers of disease and drug resistance. Here we will discuss the latest findings on Leishmania EVs, as well as potential avenues for their future development and clinical applications.
The seventh webinar is part of the cycle of conferences held every two months in preparation for the seventh version of WorldLeish, a global congress on leishmaniasis convened every four years in a different country. The 7th WorldLeish congress will take place from the 1st to the 6th of August 2022, in Cartagena, Colombia.
Join the webinar here: